(E)-1-(4-chlorophenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-1-(4-chlorophenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one
• 英文别名: 1-(4-Chlorophenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one
• 化学式: C₁₅H₁₁ClO₃
• 分子量: 274.704
• InChiKey: NPDXBNMNUDCDHM-LREOWRDNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3,4-二(四氢吡喃-2-氧基)苯甲醛 在 barium dihydroxide 、 对甲苯磺酸 作用下， 以 甲醇 为溶剂， 反应 23.0h， 生成 (E)-1-(4-chlorophenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one
  参考文献：
  名称：

  3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors

  摘要：

  A novel series of 3,4-dihydroxychalcones was synthesized to evaluate their effects against 5-lipoxygenase and cyclooxygenase. Almost all compounds exhibited potent inhibitory effects on 5-lipoxygenase with antioxidative effects, and some also inhibited cyclooxygenase. The 2',5'-disubstituted 3,4-dihydroxychalcones with hydroxy or alkoxy groups exhibited optimal inhibition of cyclooxygenase. We found that 2',5'-dimethoxy-3,4-dihydroxychalcone (37; HX-0836) inhibited cyclooxygenase to the same degree as flufenamic acid and 6-lipoxygenase, more than quercetin. Finally, these active inhibitors of 5-lipoxygenase inhibited arachidonic acid-induced mouse ear edema more than phenidone.

  DOI：

  10.1021/jm00076a019

文献信息

• Study on the substituents' effects of a series of synthetic chalcones against the yeast Candida albicans
  作者：D. Batovska、St. Parushev、A. Slavova、V. Bankova、I. Tsvetkova、M. Ninova、H. Najdenski

  DOI：10.1016/j.ejmech.2006.08.012

  日期：2007.1

  A large series of chalcones were synthesized and studied for activity against Candida albicans. The SAR analysis showed that the antifungal activity was highly dependent on the substitution pattern of the aryl rings and correlated to a large extent with the ability of compounds to interact with sulfhydryl groups. The most active were the hydroxylated chalcones as their activity related to the location

  合成了大量查耳酮，并研究了其对白色念珠菌的活性。SAR分析表明，抗真菌活性高度依赖于芳基环的取代方式，并在很大程度上与化合物与巯基相互作用的能力有关。最具活性的是羟基化查耳酮，因为它们的活性与芳基环B中酚基的位置有关，如下所示：o-OH> p-OH约为3,4-di-OH> m-OH。获得的这些相关性和其他相关性极大地有助于设计抗候选查耳酮。
• Synthesis and evaluation of butein derivatives for in vitro and in vivo inflammatory response suppression in lymphedema
  作者：Kangsan Roh、Jung-hun Lee、Hee Kang、Kye Won Park、Youngju Song、Sukchan Lee、Jin-Mo Ku

  DOI：10.1016/j.ejmech.2020.112280

  日期：2020.7

  factor α (TNF-α) production. Butein derivatives were synthesized and evaluated to identify compounds with in vitro anti-inflammatory activity. Among them, 20 μM of compounds 7j, 7m, and 14a showed 50% suppression of TNF-α production in mouse peritoneal macrophages after lipopolysaccharide stimulation. Compound 14a, exhibited the strongest potency with an in vitro IC50 of 14.6 μM and suppressed limb

  在本文中，我们证明，butein（1）可以通过抑制肿瘤坏死因子α（TNF-α）的产生来预防小鼠淋巴水肿模型中的肿胀。合成并评估了Butein衍生物，以鉴定具有体外抗炎活性的化合物。其中，20μM化合物7j，7m和14a在脂多糖刺激后表现出50％的抑制小鼠腹膜巨噬细胞TNF-α产生的作用。在鼠淋巴水肿模型中，化合物14a表现出最强的效力，体外IC50为14.6μM，肢体体积抑制了70％。在药代动力学研究中，通过口服给药，前药策略使化合物1的动力学溶解度增加了6倍，血液中的活性代谢产物水平提高了5倍，从而使化合物14a处于血液中。
• Antifungal activity of chalcones: A mechanistic study using various yeast strains
  作者：K.L. Lahtchev、D.I. Batovska、St.P. Parushev、V.M. Ubiyvovk、A.A. Sibirny

  DOI：10.1016/j.ejmech.2007.12.027

  日期：2008.10

  We reported the synthesis, antifungal evaluation and study on substituent effects of 21 chalcones. A lot of genetically defined strains belonging to different yeast genera and species, namely Saccharomyces cerevisiae, Hansenula polymorpha and Kluyveromyces lactis, were used as test organisms. Concerning the mode of the antifungal action of chalcones it was shown that DNA was probably not the main target for the chalcones. It was revealed that the yeast's intracellular glutathione and cysteine molecules play significant role as defence barrier against the chalcone action. It was also shown that chalcones may react with some proteins involved in cell separation. (C) 2008 Elsevier Masson SAS. All fights reserved.
• Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia
  作者：Pierre Regenass、Dayana Abboud、François Daubeuf、Christine Lehalle、Patrick Gizzi、Stéphanie Riché、Muriel Hachet-Haas、François Rohmer、Vincent Gasparik、Damien Boeglin、Jacques Haiech、Tim Knehans、Didier Rognan、Denis Heissler、Claire Marsol、Pascal Villa、Jean-Luc Galzi、Marcel Hibert、Nelly Frossard、Dominique Bonnet

  DOI：10.1021/acs.jmedchem.8b00657

  日期：2018.9.13

  We previously reported Chalcone-4 (1) that binds the chemokine CXCL12, not its cognate receptors CXCR4 or CXCR7, and neutralizes its biological activity. However, this neutraligand suffers from limitations such as poor chemical stability, solubility, and oral activity. Herein, we report on the discovery of pyrimidinone 57 (LIT-927), a novel neutraligand of CXCL12 which displays a higher solubility than 1 and is no longer a Michael acceptor. While both 1 and 57 reduce eosinophil recruitment in a murine model of allergic airway hypereosinophilia, 57 is the only one to display inhibitory activity following oral administration. Thereby, we here describe 57 as the first orally active CXCL12 neutraligand with anti-inflammatory properties. Combined with a high binding selectivity for CXCL12 over other chemokines, 57 represents a powerful pharmacological tool to investigate CXCL12 physiology in vivo and to explore the activity of chemokine neutralization in inflammatory and related diseases.
• [EN] COMPOSITION FOR TREATMENT, PREVENTION, OR AMELIORATION OF LYMPHEDEMA<br/>[FR] COMPOSITION POUR LE TRAITEMENT, LA PRÉVENTION OU L'AMÉLIORATION DU LYMPHŒDÈME<br/>[KO] 림프부종의 치료, 예방 또는 개선용 조성물
  申请人：GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR

  公开号：WO2021210925A1

  公开（公告）日：2021-10-21

  본 발명은 림프부종의 치료, 예방 또는 개선 효과를 나타내는 신규 화합물, 및 이를 유효성분으로 포함하는 조성물에 관한 것으로서, 의약품, 기능성 식품 또는 식품보충제, 또는 화장품으로 적용될 수 있다. 본 발명에 따른 유효성분 화합물은 TNFα 생성 억제 활성, 대사 안정성, 가용성, 혈액 노출 등 다양한 측면에서 림프부종에 대해 현저하게 개선된 효과를 나타낸다.